Steven M. Choi

Kimberly-Clark (Nasdaq: KMB) in its pending $48.7 billion acquisition of Kenvue (NYSE: KVUE), a provider of consumer health products

Waters Corporation (NYSE: WAT) in its $39 billion Reverse Morris Trust combination with Becton, Dickinson and Company's (NYSE: BDX) Biosciences & Diagnostics Solutions business to create a life sciences and diagnostics leader

Eli Lilly and Company (NYSE: LLY) in its $1.3 billion acquisition of Verve Therapeutics (Nasdaq: VERV), a pharmaceutical company developing genetic medicines for cardiovascular disease

Kimberly-Clark Corp. (NYSE: KMB) in its pending $3.4 billion strategic partnership with Suzano (NYSE: SUZ) which will create an international tissue and professional products company

Paycor (Nasdaq: PYCR) in its $4.1 billion sale to Paychex (NYSE: PAYX)

Butterfly Equity in its $1.95 billion acquisition of The Duckhorn Portfolio (NYSE: NAPA)

Eli Lilly (NYSE: LLY) in its $3.2 billion acquisition of Morphic Holding (Nasdaq: MORF)

R1 RCM (Nasdaq: RCM) in its $8.9 billion sale to TowerBrook Capital Partners and Clayton, Dubilier & Rice

Crown Laboratories, a portfolio company of Hildred Capital Management, in its pending $924 million acquisition of Revance Therapeutics (Nasdaq: RVNC)

Gamut Capital Management in its acquisition of the Airtron business of NRG Energy (NYSE: NRG)

EQT (NYSE: EQT) in its $35 billion merger with Equitrans (NYSE: ETRN)

Harman International in its acquisition of Roon Labs

Eli Lilly in its $1.4 billion acquisition of Point Therapeutics (Nasdaq: PNT)

KKR in its $1.6 billion acquisition of CIRCOR (NYSE: CIR)

CIRCOR in the sale of DeltaValve and TapcoEnpro to SCF Partners

Ruth’s Hospitality Group (Nasdaq: RUTH) in its $715 million sale to Darden (NYSE: DRI)

Cvent (Nasdaq: CVT) in its $4.6 billion sale to Blackstone

Vista Equity Partners in its $2.6 billion acquisition of Duck Creek Technologies (Nasdaq: DCT)

Paya (Nasdaq: PAYA) in its $1.3 billion sale to Nuvei (Nasdaq: NVEI)

Eli Lilly in its acquisition of Akouos (Nasdaq: AKUS)

Investindustrial in its $950 million acquisition of a significant portion of TreeHouse Foods’ (NYSE: THS) meal preparation division

Ping Identity (NYSE: PING) in its $2.8 billion sale to Thoma Bravo

Twilio (NYSE: TWLO) on its partnership with and $750 million investment in Syniverse

Allwyn Entertainment in its $9.3 billion business combination with Cohn Robbins Holdings Corp (NYSE: CRHC)

Commercial Metals Company (NYSE: CMC) in its $550 million acquisition of Tensar, a portfolio company of Castle Harlan

Blue Owl Capital (NYSE: OWL) in its $1.6 billion acquisition of Oak Street Real Estate Capital

Gamut Capital Management in its acquisition of Davis-Standard, a portfolio company of ONCAP Advisors

Davis-Standard’s acquisition of Extrusion Technology Group

Stone Point Capital in its strategic investment in Lincoln Property Company

Welsh, Carson, Anderson & Stowe in its investment in LINQ

KKR in its acquisition of a majority position of FGS Global

Coherent (Nasdaq: COHR) in its initially announced $5.7 billion sale to Lumentum (Nasdaq: LITE), followed by Coherent’s responses to competing acquisition proposals from MKS Instruments, II-VI and Lumentum, culminating in Coherent’s $7.1 billion sale to II-VI (Nasdaq: IIVI)*

KEMET (NYSE: KEM) in its $1.8 billion acquisition by Yageo*

H.I.G. Bayside Capital in the sale of its portfolio company, Jackson Hewitt Tax Service, to Corsair Capital*

Litera, a portfolio company of Hg Capital, in its acquisition of Kira Systems*

Hg Capital in its investment in Sovos through the Hg Saturn 2 fund*

Cemex España in its tender offer to acquire a minority stake in Cemex Latam*

KAR Auction Services (NYSE: KAR) in its spin-off of IAA (NYSE: IAA)*

Altaba (Nasdaq: AABA) in its plan of liquidation and dissolution*

HC2 Holdings (NYSE: HCHC) in connection with its common stock rights offering and its settlement with dissident MG Capital following a consent solicitation and threatened proxy contest*

Healios K.K. in connection with its cooperation agreement with Athersys (Nasdaq: ATHX)*

Aurinia Pharmaceuticals (Nasdaq: AUPH) in connection with its successful proxy contest against dissident ILJIN*

Akamai (Nasdaq: AKAM) in its response to and settlement with activist shareholder Elliott*

*Prior to joining Kirkland